🩺 Genetic signs of leukemia may appear years before diagnosis
A recent study revealed the possibility that genetic changes may appear in blood cells years before the symptoms of chronic leukemia emerge. These genetic markers help predict disease progression, identify patients who may need follow-up and early treatment, and distinguish other cases that may be due to normal aging rather than a cancerous disease.
This research highlights the importance of using whole-genome sequencing to analyze the progression of chronic leukemia, especially myeloproliferative neoplasms (myeloproliferative neoplasms – MPNs), a rare and long-lasting type of blood disease that originates in the bone marrow.
🧬 How does chronic leukemia arise?
Myeloproliferative neoplasms result from uncontrolled production of specific blood cells in the bone marrow. In the United Kingdom, around 40,000 people live with this condition, and about 4,000 new cases are diagnosed each year.
These tumors usually begin with genetic mutations that appear early and then accumulate over decades. The most common mutations are associated with the JAK2, CALR, and MPL genes, but about 10% of patients do not have these known mutations, which causes difficulties in accurate diagnosis.
In these cases, doctors often rely on the appearance of bone cells to diagnose cancer, and this may lead to some patients being treated as cancer patients despite the lack of conclusive genetic evidence.
🧪 Why do some patients worsen?
The course of chronic leukemia varies greatly between patients; some remain stable for years with simple treatment, while others deteriorate into more severe conditions such as leukemia or myelofibrosis.
The inability to predict which patients will progress pushed researchers to study the relationship between genetic mutations and the future of the disease, as well as the condition of patients who do not show mutations in the known genes.
30 patients were followed through more than 450 blood and bone marrow samples via repeated genomic tests, with about 8,000 blood test results and treatment records added in a unique experiment that lasted up to 25 years.
🧠 Building family trees for blood-cell genes
The researchers used DNA data from blood cells to build “family trees” that reveal the origin and stages of development of cancer clones that drive disease worsening.
The analyses showed two distinct patterns:
- Patients whose condition was primarily stable had genetically stable blood cells with few or no mutations.
- Patients whose disease progressed accumulated additional DNA mutations over time.
This means that genetic shifts may specialize the disease course for patients and make it possible to detect the beginning of deterioration years before changes in symptoms and routine clinical tests.
🌱 Do all diagnoses mean cancer?
For patients who did not carry JAK2, CALR, or MPL mutations, the researchers found that the genetic patterns of their blood cells were closer to those associated with normal aging rather than cancer.
This suggests that some cases previously diagnosed as blood cancer may have been incorrectly classified, and their causes may be related to biological traits without being a true cancer.
As a result of these findings, the British Society for Haematology recommended following new guidelines that advise describing some patients as thrombocytosis cases (elevated platelet count) without JAK2, CALR, or MPL mutations instead of an early diagnosis of leukemia.
🩺 The importance of routine genetic monitoring
The study results indicate multiple benefits of repeated genetic analysis for medical monitoring:
- Distinguishing stable disease from cases at risk of deterioration.
- More accurate diagnosis of ambiguous cases.
- Better understanding of disease progression and support for developing more precise treatments.
Regular genetic tests may allow high-risk patients to be followed before their condition progresses to dangerous stages, opening the door to early intervention. In contrast, this approach helps avoid costly and unnecessary treatments for those who do not have a real disease.
✍ Statements from specialists and patients
The lead researcher explained that “following patients over years and using genetic analysis enabled us to track the development of blood cells and monitor the different patterns of progression among patients.” The director of research management added: “We are living in a golden age of research in which we can read the DNA code quickly to discover the mistakes that lead to cancer.” The consultant doctor also noted the difficulty of predicting the disease course, but praised the value of combining continuous care with genetic analysis in improving patient follow-up.
One patient, who has had a rare form of MPN for more than 30 years, offered testimony that reflects the real-world challenges of the disease and the hope that research participation can improve the future for other patients.
🧪 Conclusion
This scientific research highlights the vital role of genetic markers in revealing the long-term progression of chronic leukemia. By building “family trees” for blood cells, scientists and doctors can monitor the mutations that determine the course of the disease, opening horizons for early diagnosis and accurate information that help improve treatment management.
Pointing out diagnostic cases that may reflect aging rather than cancer also pushes the medical community to reassess diagnostic tests, which enhances accuracy and protects patients from the risk of unnecessary treatments.
These steps represent real progress in the field of blood health and cancer, and they may pave the way in the future for routine genomic monitoring that delivers major benefits to patients.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
